Scleroderma pathophysiology
- Endothelial injury and vasculopathy:The initiating event is microvascular endothelial injury — endothelial apoptosis, loss of NO production, upregulation of endothelin-1, and VEGF dysregulation that paradoxically produces aberrant rather than effective angiogenesis. Capillary loss in nailfold capillaroscopy is diagnostic. This vasculopathy underlies Raynaud’s phenomenon and pulmonary arterial hypertension (PAH) — the leading causes of scleroderma morbidity and mortality.
- Fibrosis:Fibroblast activation via TGF-β1 signalling drives progressive collagen deposition in skin (diffuse or limited cutaneous SSc), lungs (interstitial lung disease), heart, and GI tract. TGF-β1 signalling is partially downstream of oxidative stress — NOX4 (not NOX2) is the primary ROS source in scleroderma fibroblasts. Phycocyanobilin preferentially inhibits NOX2; the NOX4-fibroblast pathway is less well addressed.
- Immune dysregulation:Th2 and Th17 skewing, elevated IL-4, IL-13 (fibrosis-promoting cytokines), and anti-topoisomerase (Scl-70) or anti-centromere antibodies. Treatment ranges from hydroxychloroquine to mycophenolate mofetil and cyclophosphamide (for ILD). Newer therapies: nintedanib (anti-fibrotic tyrosine kinase inhibitor) and tocilizumab.
GI involvement and nutrition
- Oesophageal dysmotility:The most common GI manifestation (>90% of patients). Impaired lower oesophageal sphincter tone causes GERD; impaired peristalsis causes dysphagia. Spirulina powder dissolved in water or juice is an appropriate form for scleroderma patients with dysphagia — tablets are more difficult to swallow.
- Gastroparesis and SIBO:Gastric dysmotility delays emptying and promotes bacterial overgrowth in the small intestine. SIBO causes malabsorption of fat-soluble vitamins, B12, and iron. As in standalone SIBO (see that article), spirulina polysaccharides may worsen SIBO — introduce at low dose (1–2 g) and monitor GI symptoms carefully.
- Malnutrition:Dysphagia, gastroparesis, malabsorption, and reduced appetite collectively cause malnutrition in advanced scleroderma. Spirulina’s nutrient density (protein, iron, B vitamins, gamma-linolenic acid) in a liquid format is practically relevant for these patients.
Vascular mechanisms: the most compelling rationale
- Scleroderma Raynaud’s is both vasospastic (like primary Raynaud’s) and structural (loss of capillaries, fibrotic digital arteries). The vasospastic component is addressable by NO preservation; the structural component is not. Phycocyanobilin’s endothelial NOX2 inhibition addresses the vasospastic component.
- Endothelin-1 elevation in scleroderma is one of the strongest in any disease — PAH in scleroderma is managed with endothelin receptor antagonists (bosentan, ambrisentan). NF-κB inhibition by phycocyanobilin reduces endothelin-1 transcription — complementary to ERA treatment mechanistically.
Drug interactions
- Bosentan/ambrisentan (endothelin receptor antagonists for PAH):Metabolised by CYP3A4 and CYP2C9 (bosentan is an inducer). No documented spirulina pharmacokinetic interaction. These drugs require monthly LFT monitoring — spirulina at standard doses does not impair liver function.
- Nintedanib (antifibrotic for ILD):Tyrosine kinase inhibitor with significant GI side effects (diarrhoea, nausea). Spirulina’s GI polysaccharides may worsen GI side effects of nintedanib. Introduce spirulina carefully if nintedanib-related GI issues are ongoing. No pharmacokinetic interaction documented.
- Mycophenolate mofetil:Used for ILD and skin disease. Immune activation from spirulina (NK stimulation) requires specialist assessment, as in other immunosuppressive contexts.
Practical guidance
- Discuss with rheumatologist or scleroderma specialist before starting — particularly if on immunosuppression, ERA therapy, or nintedanib
- Use powder format dissolved in juice — practical for dysphagia; cold format for phycocyanin preservation
- Start at 1–2 g/day and increase slowly given GI dysmotility and SIBO risk; target 3–5 g/day if tolerated
- The vascular rationale (NO preservation, endothelin-1 reduction) is the most compelling mechanism for scleroderma Raynaud’s and vasculopathy
- Monitor GI symptoms at each dose increase — SIBO exacerbation presents as increased bloating, altered bowel habit, and abdominal discomfort